GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (FRA:0RA) » Definitions » Effective Interest Rate on Debt %

RAPT Therapeutics (FRA:0RA) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. RAPT Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2024 was €0.00 Mil. RAPT Therapeutics's average total debt for the quarter that ended in Jun. 2024 was €5.57 Mil. Therefore, RAPT Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 was 0.00%.


RAPT Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for RAPT Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics Effective Interest Rate on Debt % Chart

RAPT Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - - -

RAPT Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RAPT Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, RAPT Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RAPT Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's Effective Interest Rate on Debt % falls into.



RAPT Therapeutics Effective Interest Rate on Debt % Calculation

RAPT Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (8.486+6.333)/ 2 )
=-1  *  0/7.4095
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.437 + 2.049
=8.486

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.088 + 2.245
=6.333

RAPT Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Mar. 2024 )+Total Debt  (Q: Jun. 2024 ))/ count )
=-1  *  0/( (5.817+5.321)/ 2 )
=-1  *  0/5.569
=0.00 %

where

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.51 + 2.307
=5.817

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.935 + 2.386
=5.321

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


RAPT Therapeutics  (FRA:0RA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


RAPT Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


RAPT Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
561 Eccles Avenue, South San Francisco, CA, USA, 94080
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Headlines

No Headlines